VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxart, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026
- Market cap
- $115.15M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Vaxart, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Government Contract [Member] | $224.52M | $24.86M | $0 | – | $0 | $0 | -$20.00K | $1.34M | 94.6% | +803.2% |
| License [Member] | $8.71M | $0 | – | – | – | – | – | – | 3.7% | – |
| Collaboration Revenue [Member] | $2.11M | $0 | – | – | – | – | – | – | 0.9% | – |
| Non Cash Royalty Revenue [Member] | $1.93M | $3.84M | $3.92M | $107.00K | $879.00K | $886.00K | $5.03M | $1.48M | 0.8% | -49.8% |
| Royalty [Member] | – | – | – | – | $0 | $2.96M | $4.45M | $1.34M | – | – |
| Customer Service Contracts [Member] | – | – | – | $0 | $13.00K | $198.00K | $406.00K | – | – | – |
| Grant [Member] | – | $0 | $3.46M | $0 | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Vaxart's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.